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Introduction 
Pyoderma gangrenosum is a rare autoinflamma-tory 
ulcerative skin disease, affecting 2-10 people per 
million per year [1]. It presents as a painful deep 
ulceration with an irregular violaceous border most 
commonly located on the lower extremities [2]. 
There is no standard treatment for this neutrophilic 
dermatosis. Treatment addresses the underlying 
disease, inflammation, pain control, and wound 
management [1]. Management of the inflammatory 
nature of the disease has been studied extensively, 
although evidence for the optimal wound care 
regimen is lacking. This study examines the use of 
gentian violet for wound care as an adjuvant to 
systemic treatment for pyoderma gangrenosum. 
 
Methods 
This retrospective chart review was approved by the 
Wake Forest Baptist Health institutional review 
board. Inclusion criteria consisted of patients over 
the age of 18 years diagnosed with pyoderma 
gangrenosum and treated with gentian violet at the 
Wake Forest School of Medicine Department of 
Dermatology between August 2008 and August 
2018. The wound care regimen involved applying 2% 
gentian violet without any dilutions to the affected 
area with a cotton ball or Q-tip once a week, covering 
with petrolatum jelly gauze, then wrapping with an 
Unna boot or Coban. Systemic therapy was not 
routinely altered when gentian violet was added to 
the wound care regimen. The primary outcome was 
documented clinical improvement. Additional data 
collected included anatomic location of pyoderma 
gangrenosum, concurrent or previous systemic 
therapy, antibiotic use, and number of gentian violet 
treatments. Demographic data collected included 
age and sex. Exclusion criteria included patients 
without pyoderma gangrenosum, patients not 
treated with gentian violet, and patients with less 
than two visits. 
Abstract 
Pyoderma gangrenosum is a rare autoinflammatory 
skin disease. Treatment is multifactorial, addressing 
inflammation, pain, underlying disease, if present, 
and the wound. Gentian violet has been used for 
hundreds of years in a variety of dermatologic 
conditions for its anti-inflammatory properties. This 
study aims to evaluate gentian violet in wound 
healing for pyoderma gangrenosum. We conducted 
a retrospective chart review of patients with 
pyoderma gangrenosum treated with gentian violet 
at the Wake Forest School of Medicine Department of 
Dermatology in the last 10 years. The primary 
outcome was clinical improvement. Of the 34 cases 
that met inclusion criteria, 70% improved with 
gentian violet, 24% had no documented change, 3% 
initially improved then worsened, and 3% had 
unclear results. Gentian violet is a safe and cheap 
treatment that may improve resolution of pyoderma 
gangrenosum lesions in addition to systemic 
therapy. 
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Results 
Thirty-one patients met inclusion criteria, with 34 
total cases, defined as separate locations to which 
gentian violet was applied and response to 
treatment was monitored. The average patient age 
was 56 years. Seventy-one percent of patients were 
female. All patients had ulcers on the lower 
extremities; one patient also had pyoderma 
gangrenosum on her arm and abdomen (Table 1). 
Seventy percent of the pyoderma gangrenosum 
cases improved upon follow-up, 24% did not 
improve, 3% initially improved then worsened, and 
3% had unclear results. The average number of 
gentian violet treatments was 8, ranging from one to 
>50. All the patients were also prescribed systemic 
treatment. The most common systemic therapies 
used were prednisone (87%) and methotrexate 
(52%). Fifty-two percent of patients took antibiotics 
at some point throughout the course of treatment. 
There were no adverse effects reported with the use 
of gentian violet. 
 
Discussion 
Gentian violet has been used in the treatment of 
dermatologic diseases since the 1800s [3]. 
Historically, gentian violet has been used to treat 
angular cheilitis, decubitus ulcers, impetigo, 
infectious erosions, methicillin-resistant 
Staphylococcus aureus nasal carriage, paronychia, 
thrush, and umbilical infections [4]. It has analgesic 
effects, improves wound healing, and has no 
documented adverse reactions [5]. 
The definition of improvement was not clearly stated 
in the medical records. We hypothesize that the lack 
of documented improvement in 24% of cases was 
related to a lack of reduction in wound size, but that 
the inflammation at the border had likely decreased, 
leading to a positive Gulliver sign, or transition from 
the inflammatory to healing stages of pyoderma 
gangrenosum [6]. This highlights the need for a 
standardized, validated measure of pyoderma 
gangrenosum severity that can be monitored 
throughout treatment. Another limitation of this 
study is that patients were not randomized to 
gentian violet or control. 
 
Conclusion 
Patients and physicians seem to appreciate that this 
topical treatment is low risk, safe, widely available, 
and inexpensive. A 2% solution of gentian violet 
costs $0.16 per milliliter [3]. The lack of any 
detectable adverse effects in our study, along with 
the low cost and ease of use, suggest that gentian 
violet may be beneficial to use as adjuvant to 
systemic therapy in order to improve wound healing 
in patients with pyoderma gangrenosum. 
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Table 1. Characteristics of patients with pyoderma gangrenosum treated with gentian violet. 
Age Sex 
Disease 
Duration Location Systemic therapy Oral antibiotics
# of GV 
treatments Improved
48 F >5y R leg Pred, MTX, MMF Minocycline 2 Yes 
70 M 30y L leg Pred, MMF, IVIG Cephalexin 12 No
54 F >5y L leg Pred, MTX, CSA, Ertapenem, clindamycin 11 Yes 
77 F >5y R leg, R thigh Pred, MMF Cephalexin 14 Yes
62 M >40y L leg 
Pred, methylprednisolone, 
CSA None 1 No 
29 M >5y 
L thigh, R foot, 
bilateral 
ankles
Pred, MTX Vancomycin, Pip/Tazo 
Thigh-1 
Foot-3 
Ankle-2 
Yes-thigh 
No change-
foot and ankle
62 F >10y R leg Pred, MMF Cephalexin >50 Yes
87 F >5y L leg CSA None 1 Unclear 
70 F >5y L leg MTX, thalidomide None 1  Yes
28 F >5y R leg Prednisolone, Pred TMP-SMX 1 No
54 F 2y R leg 
Pred, MTX, adalimumab, 
infliximab Doxycycline 15 Yes 
81 F 2y Bilateral legs Pred None 4 Yes 
60 M 6y L leg CSA None 2 Yes 
30 F 7y L leg 
Pred, adalimumab, 
ustekinumab, thalidomide, 
CSA, MTX
Ciprofloxacin, 
cephalexin  1 Yes 
33 F 11y L leg Pred, MTX, dapsone, 
adalimumab
None 1 Yes 
62 F 2y Bilateral legs Pred, AZA None 4 Yes then No 
72 F 3mos L leg,  R leg Pred, MTX Cephalexin 
L leg-32 
R leg-8 
L leg-Yes 
R leg-Yes 
63 F 3y L leg Pred, dapsone None 36 Yes
29 F 3mos R leg L leg Pred None 12 Yes 
24 M 1y R leg Pred, MTX None 1 Yes
54 F 20y L leg Pred, dapsone Ciprofloxacin, 
doxycycline
5 Yes 
60 F 2y L leg Pred, dapsone, MTX, MMF, 
thalidomide, CSA
None 8 Yes 
58 M 1y Bilateral legs Pred, thalidomide, IVIG TMP-SMX 5 Yes 
85 M 2y L leg Pred, AZA, MMF None 4 Yes
44 M 1y L leg Pred, MTX, adalimumab, MMF
Clindamycin, 
doxycycline 4 Yes 
44 M 1y L leg, L arm, R abdomen Pred, MTX, CSA 
Doxycycline, 
minocycline 25 No 
83  F 5y Bilateral ankles Pred, MTX, CSA None 1 No
56 F 1y Bilateral legs Pred, MTX None 2 Yes 
53 F 8 y R leg Pred, MTX None 6 Yes
56 F >5y Bilateral legs Dapsone, adalimumab, rifampin, etanercept Clindamycin 2 No 
54 F 3y R leg, L groin and buttocks Pred, MTX, adalimumab Doxycycline 4 Yes 
 
AZA=azathioprine, CSA=cyclosporine, F=female, GV=gentian violet, IVIG=intravenous immunoglobulin, L=left, M=male, mos =months, 
MMF=mycophenolate mofetil, MTX=methotrexate, Pip=piperacillin, Pred= prednisone, R=right, Tazo=tazobactam, TM-SMX=trimethoprim-
sulfamethoxazole
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